RE:RE:RE:Will THTX backtrack from these statements??JFM1330 - you have lost your moorings. Time to calm down a bit and try and see things more accurately.
Let me try and help you do that:
1.) The company stated just before the OO that the legacy drug revenues would grow at 20-25% annually. Immediately after, they stopped saying that and produced a real dud on sales in Q1. I will let you decide how you would like to characterize that but it is just a fact. Furthermore, the company itself acknowledged to me even before this that they had a credibility problem with investors due to their seriously off-the-mark sales forecasts for both Egrifta and Trogarzo. So, they even agree they have a credibility issue. Frankly, I think you agree with that as well. Also, I ahve been in this business for over 40 years and have seen companies lie to get deals done at as attractive a price as they can many times. I am not freaked out by it at this point and neither should you. But denying that it happened is not sensible. Companies lie all the time usually not by not telling the truth but by not telling the whole truth or by not telling nothing but the truth. It just comes with the territory. You have concluded incorrectly that some of us desiring the company to more aggressively market what they have as us wanting them to lie about what they have. That is an unsuuportable assertion.
2.) You are just making up the whole thing about some of us wanting the company to lie as much as they possibly can. If you go back and check out some of my earlier posts about the situation on the 20-25% sales growth claim you will see me raking the company over the coals for blowing up their credibility once again by lying about that. So, I hate to say it, but you are flat-out lying about what I have said and totally mis-characterizing my point of view on this and other things. Do you really think that after holding TH for the better part of 15 years I am looking for them to pump it so I can dump it???? It is not a good look for you and is totally unnecessary. We have had many legitimate debates on the issues and there is no need to dive into the muck like that. Stay classy JFM!
3.) If I am bitter, I must be a very strange bitter person as I am happy to give credit where and when it is due to the company and its executives. Bitter people spew hate non-stop and cannot see any situation as it really is. It seems like some people can struggle with any criticism at all and cannot tolerate a fair-minded look at the situation if that also involves legitimate criticism. It is just a fact that TH is undervalued versus lesser companies. It is just a fact that despite hiring two IR consultants and an experienced IR officer that stock remains undervalued versus lesser companies. I really don't have a good explanation for that as it seems the company has tried to do the right thing in regards to IR but the results are still what they are.
I recommend a good long walk and maybe taking a few days off posting so that you can get your head sorted out a bit and realize that most of what you just posted was far off the mark.
jfm1330 wrote: Wow! Now I learned that the management of the company is likely dishonest. But you still think that the stock of a company likely lying on important financial stuff is undervalued. You are hard to follow... But I finally got it, the stock price is so undervalued because the market cannot trust a management that likely lies on important matters. So if they lied there, why not on oncology potential, why not on NASH real approval potential?
So oncology has zero value, the management likely lied on sales growth, they are blowing up their credibility with investors. I now understand why some are pushing for a CYDY pumping approach. In fact, what you are asking the management is this: don't just lie a bit, if you are to lie, lie the whole way. Pump the stock price out of nothing so we can sell.
All that is not serious. The level of bitterness here is out of control.
SPCEO1 wrote: They already backtracked last quarter on the sales growth statement. I forget the exact wording but it was something that suggested tepid growth short term and better growth long term. My belief is that the 20-25% projection was made just to support the OO. They knew it was nonsense at the time. So, yes management likely lied to investors about that and then quickly retracted it when Q1's ugly results were released. You may remember me fuming about them blowing up their credibility with investors again.
longterm56 wrote: Although TXTH has been very tight-lipped (wow, that's an understatement), there are two statements directly from Paul that he has not yet retracted or modified (from what I recall):
- NASH trial to begin in 3rd quarter
- 20-25% Q/Q growth of revenues from Egrifta & Trogarzo.
We'll see if he comments on or retracts either of these on Thursday.
-LT